Our top pick for
Building a portfolio
Dicerna Pharmaceuticals, Inc is a biotechnology business based in the US. Dicerna Pharmaceuticals shares (DRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Dicerna Pharmaceuticals employs 302 staff and has a trailing 12-month revenue of around USD0.00.
|52-week range||USD$16.5 - USD$29.9|
|50-day moving average||USD$26.602|
|200-day moving average||USD$23.7976|
|Wall St. target price||USD$37.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.376|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$164.3 million|
|Gross profit TTM||USD$-41,077,000|
|Return on assets TTM||-10.84%|
|Return on equity TTM||-77.77%|
|Market capitalisation||USD$2.1 billion|
TTM: trailing 12 months
There are currently 5.3 million Dicerna Pharmaceuticals shares held short by investors – that's known as Dicerna Pharmaceuticals's "short interest". This figure is 3.2% up from 5.2 million last month.
There are a few different ways that this level of interest in shorting Dicerna Pharmaceuticals shares can be evaluated.
Dicerna Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Dicerna Pharmaceuticals shares currently shorted divided by the average quantity of Dicerna Pharmaceuticals shares traded daily (recently around 932666.19964974). Dicerna Pharmaceuticals's SIR currently stands at 5.71. In other words for every 100,000 Dicerna Pharmaceuticals shares traded daily on the market, roughly 5710 shares are currently held short.
However Dicerna Pharmaceuticals's short interest can also be evaluated against the total number of Dicerna Pharmaceuticals shares, or, against the total number of tradable Dicerna Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Dicerna Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Dicerna Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0.0738% of the tradable shares (for every 100,000 tradable Dicerna Pharmaceuticals shares, roughly 74 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Dicerna Pharmaceuticals.
Find out more about how you can short Dicerna Pharmaceuticals stock.
We're not expecting Dicerna Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Dicerna Pharmaceuticals's shares have ranged in value from as little as $16.5 up to $29.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dicerna Pharmaceuticals's is 1.0485. This would suggest that Dicerna Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Dicerna Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.